About Us

Broad services. Innovative approaches. Deep experience.

ILS delivers Toxicology Services for your research and regulatory compliance needs.

We created ILS as a provider of integrated, comprehensive, multidisciplinary support for clients needing toxicology support for research and regulatory compliance. Our aim? To combine scientific excellence with efficient and effective management, so we could handle everything from the everyday to the never-before-seen in a responsive and cost-effective manner.

Decades later, building on that distinctive and now well-proven platform, ILS plays an important role in exciting and rewarding areas of toxicology:

Headquartered in Research Triangle Park, North Carolina, our team of more than 100 scientists and support staff is proud to help improve the quality of human health, and further efforts to make the world a better and safer place.


ILS occupies almost 50,000 square feet of advanced research and office space in the Research Triangle Park area of North Carolina. Our purpose-built laboratories, vivarium and office space were designed and built with redundant critical systems to maximize security, increase efficiency and minimize downtime. The facilities are compliant with all relevant national and international guidelines, regulations and Good Laboratory Practice (GLP) requirements.

  • Animal facility accredited by the AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) since 1993
  • Laboratories, freezers and critical analytical equipment with emergency back-up power from two generators and multiple UPS systems
  • Vivarium supported by redundant, generator-backed HVAC system
  • Secure IT infrastructure designed for >99.99% uptime
  • Next generation RF-based environmental monitoring system with independent backup for critical applications such as freezers
  • On-site archives for storage at room temperature, -20 °C and -80 °C
  • Advanced security system with 24/7 electronic monitoring
  • Controlled facility access with additional authentication required for entry into all laboratories, vivarium, archives, server rooms and mechanical areas
  • All facility inspections and equipment maintenance and calibration records maintained by QA and available for sponsor review

Click here to access ILS’ Financial COI Policy and Disclosure Form.

ILS Leadership

Dr. Allen provides scientific leadership, management and direction to ILS’ programs and core services. He works closely with all scientific staff to support the planning and execution of ILS growth plans, and leads staff planning and employee development. He has over 17 years of experience in regulatory toxicology, test method validation and in vitro biology. At ILS, he serves as the Principal Investigator for the National Toxicology Program’s Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and was the 2017 recipient of the Society of Toxicology Enhancement of Animal Welfare Award. He is the current President of the American Society for Cellular and Computational Toxicology and is a past President of the Society of Toxicology In Vitro and Alternative Methods Specialty Section. Prior to joining ILS, he was a toxicologist for the Food and Drug Administration, Center for Drug Evaluation and Research, where he was responsible for evaluating toxicological and pharmacological data for investigational new drug applications. He received his B.S. in Zoology from North Carolina State University, his M.S. in Biological Sciences from the University of North Carolina at Wilmington, and his Ph.D. in Cell Biology from North Carolina State University.


Follow me!


Dr. Recio is responsible for defining the scope of work, providing oversight and organization for all studies, and training ILS staff in genetic and molecular toxicology methods. He provides supervision of all genetic toxicology and genomic-based projects through prioritization, coordination and scheduling of all activities. He also guides the development of new capabilities for novel approaches for use in the assessment of genotoxicity, and works with ILS staff to develop new programs and provide new avenues for research projects. He received both his M.S. and Ph.D. in Toxicology from the University of Kentucky. Dr. Recio has published more than 100 manuscripts in the peer-reviewed literature examining mode-of-action and identification of biomarkers of cytotoxicity, genotoxicity, and mutagenicity. Dr Recio served on board of Councilors for the North Carolina Chapter of the Society of Toxicology (2006-2008), and in 2006 was the President of the Genetic and Environmental Mutagenesis Society. In 2010, was appointed to the SOT Council on Diversity Initiatives and in 2012 elected President for the SOT’s Hispanic Organization for Toxicologist. In 2012 -2015 appointed to an OECD Expert Group charged with revising OECD 476 and the development of a new OECD Guidance on TK gene mutation (OECD 490). Dr Recio serves on the Editorial Board for Mutation Research – Reviews in Mutation Research and is an Associate Editor for Toxicological Sciences.


Follow me!


Mr. Blackard has more than 25 years of experience in the environmental health science industry and over 15 years of experience managing federal contracts. Before reaching his current position at ILS, he served as a Program Manager for six years, Director of Operations for two years and the Chief Operating Officer for five years. His role includes managing the daily and long-term business operations of the company, including Finance, Contracts, Human Resources, Information Technology, Quality Assurance, Health and Safety, and Facility Administration. He works with the President to assure the aggressive and successful growth of the company. He holds a B.S. in Zoology from North Carolina State University, and an MSPH in Environmental Sciences and Engineering, Environmental Management and Policy from the University of North Carolina at Chapel Hill.


Follow me!


Suzanne Phillips brings more than 17 years of experience in business development, scientific and operational roles within the pharmaceutical and CRO industries to ILS.  She leads the ILS Business Development team including marketing, sales and client communication.  Her broad expertise enables her to understand customer requirements in regulatory safety assessment and their research and development needs. Ms. Phillips works with the President and corporate management team to ensure new business development and execution of ILS growth plan.


Prior to joining ILS, Suzanne served as Senior Vice President of Scientific Operations at Gentris Corporation responsible for laboratory operations including R&D and Study Director teams.  She started her career as a molecular biologist working in drug metabolism and pharmacokinetics in safety assessment, toxicogenomics, and biomarker development in the pharmaceutical industry to include Glaxo Smith-Kline, Sanofi-Synthelabo and at a non-profit toxicology research center – CIIT.  Suzanne earned a Bachelor of Science in Zoology from North Carolina State University.


Follow me!